Personalized Dietary Feedback to Reduce Hepatic Steatosis in Patients With MASLD (PERSOMA)
Effect of Personalized Dietary and Lifestyle Feedback on Hepatic Steatosis in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Prospective, Randomized Controlled Trial
Metabolic dysfunction-associated steatotic liver disease (MASLD) and combined metabolic dysfunction and alcohol-associated liver disease (MetALD) are common chronic liver diseases associated with metabolic dysfunction and an increased risk of liver-related and cardiovascular complications. Lifestyle modification, particularly dietary changes and increased physical activity, represents a cornerstone of treatment. However, general lifestyle recommendations are often insufficient to achieve sustained improvements.
This prospective, randomized controlled trial aims to investigate whether personalized dietary and lifestyle feedback based on a structured questionnaire is more effective in reducing hepatic steatosis than generic lifestyle recommendations.
A total of 174 patients with MASLD or MetALD will be randomized 1:1 to receive either personalized or generic written feedback at baseline and after 2, 4, and 6 months. Changes in hepatic steatosis, assessed by the controlled attenuation parameter (CAP), will be evaluated over a six-month period.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a prospective, single-center, randomized controlled trial designed to evaluate the effectiveness of personalized dietary and lifestyle feedback compared with generic recommendations in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) or metabolic dysfunction and alcohol-associated liver disease (MetALD).
A total of 174 adult patients with MASLD or MetALD will be randomized in a 1:1 ratio to an intervention group receiving individualized feedback based on a structured dietary and lifestyle questionnaire or a control group receiving standardized written recommendations.
Participants will complete the questionnaire at baseline and after 2, 4, and 6 months, followed by the corresponding written feedback. Clinical, anthropometric, laboratory, and non-invasive liver assessments, including vibration-controlled transient elastography (VCTE) and controlled attenuation parameter (CAP), will be performed at baseline and after six months.
The primary objective is to compare hepatic steatosis between the two groups after six months, adjusting for baseline CAP values. Secondary objectives include assessing changes in body weight, metabolic parameters, liver stiffness, dietary habits, physical activity, and health-related quality of life.
The study aims to determine whether a simple, scalable, personalized feedback approach can improve lifestyle management in patients with MASLD or MetALD.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Georg Semmler, MD PhD
- Numéro de téléphone: +4314040047410
- E-mail: georg.semmler@meduniwien.ac.at
Lieux d'étude
-
-
State of Vienna
-
Vienna, State of Vienna, L'Autriche, 1090
- Medical University of Vienna
-
Contact:
- Georg Semmler, MD PhD
- Numéro de téléphone: +4314040047410
- E-mail: sld@meduniwien.ac.at
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18-80 years.
- Controlled attenuation parameter (CAP) >248 dB/m.
- Sufficient German language proficiency to independently complete the questionnaires.
- Written informed consent to participate in the study.
Exclusion Criteria:
- Other active chronic liver disease.
- Significant alcohol consumption, defined as ≥50 g/day in women or ≥60 g/day in men.
- Pregnancy or breastfeeding.
- Type 1 diabetes mellitus.
- Initiation or dose modification of GLP-1 receptor agonists or other weight-modifying pharmacological therapies within the previous three months.
- Planned bariatric surgery during study participation.
- Severe or unstable medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of study results.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Personalized Dietary Feedback
Participants will receive personalized written dietary feedback based on their individual responses to a structured questionnaire. The feedback will include tailored recommendations regarding dietary habits. Updated personalized feedback will be provided at baseline and after 2, 4, and 6 months. |
Participants receive individualized written dietary feedback based on their responses to a structured dietary questionnaire. The feedback includes an assessment of individual dietary habits, a visual representation of dietary patterns, and personalized recommendations to improve food choices and dietary quality. Updated feedback is provided at baseline and after 2, 4, and 6 months based on repeated questionnaire assessments. |
|
Comparateur actif: Generic Dietary Feedback
Participants will receive standardized written dietary recommendations independent of their individual questionnaire responses. Generic feedback will be provided at baseline and after 2, 4, and 6 months. |
Participants receive standardized written dietary recommendations based on general nutritional guidelines. The information is identical for all participants in the control group and is not tailored to individual dietary habits or questionnaire responses. The same generic dietary information is provided at baseline and after 2, 4, and 6 months. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Hepatic Steatosis at 6 Months, Assessed by Controlled Attenuation Parameter (CAP) Using Vibration-Controlled Transient Elastography (VCTE)
Délai: 6 months (baseline CAP used for adjustment).
|
Hepatic steatosis will be quantified using the controlled attenuation parameter (CAP), measured in decibels per meter (dB/m) by vibration-controlled transient elastography (VCTE). The outcome measure is the CAP value at 6 months. The between-group difference at 6 months will be evaluated using analysis of covariance (ANCOVA), with baseline CAP included as a covariate. CAP is the only measurement reported for this outcome. |
6 months (baseline CAP used for adjustment).
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Body Weight from Baseline to 6 Months
Délai: Baseline and 6 months
|
Body weight will be measured in kilograms (kg). Change will be calculated as body weight at 6 months minus baseline body weight. |
Baseline and 6 months
|
|
Percentage Change in Body Weight from Baseline to 6 Months
Délai: Baseline and 6 months
|
Percentage change in body weight will be calculated as [(body weight at 6 months - baseline body weight) / baseline body weight] × 100. |
Baseline and 6 months
|
|
Change in Waist Circumference from Baseline to 6 Months
Délai: Baseline and 6 months
|
Waist circumference will be measured in centimeters (cm). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Hip Circumference from Baseline to 6 Months
Délai: Baseline and 6 months
|
Hip circumference will be measured in centimeters (cm). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Alanine Aminotransferase (ALT) from Baseline to 6 Months
Délai: Baseline and 6 months
|
Serum ALT will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Aspartate Aminotransferase (AST) from Baseline to 6 Months
Délai: Baseline and 6 months
|
Serum AST will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
|
Change in Gamma-Glutamyl Transferase (GGT) from Baseline to 6 Months
Délai: Baseline and 6 months
|
Serum GGT will be measured in units per liter (U/L). Absolute change from baseline to 6 months will be reported. |
Baseline and 6 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Patient data can be shared upon reasonable request and after fulfilling all legal and data protection requirements from the EU.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .